Joshua Liang
Chief Executive Officer bei CLOVER BIOPHARMACEUTICALS, LTD.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Joshua Liang is currently the Chief Executive Officer & Director at Sichuan Clover Biopharmaceuticals, Inc. He is also the Chief Executive Officer & Executive Director at Clover Biopharmaceuticals Ltd., Clover Biopharmaceuticals USA, Inc., Clover Biopharmaceuticals Aus Pty Ltd., and Clover Biopharmaceutical Beijing Co. Ltd.
Additionally, he holds the position of General Manager & Director at Clover Biopharmaceuticals Hong Kong Ltd.
and General Manager & Executive Director at Clover Biopharmaceuticals Shanghai Co. Ltd.
Mr. Liang started his career as the General Manager & Director at Zhejiang Clover Biopharmaceutical, Inc. He completed his undergraduate degree at the University of Pennsylvania and also studied at The Wharton School of the University of Pennsylvania.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.04.2024 | 20 489 909 ( 1,58% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Joshua Liang
| Unternehmen | Position | Beginn |
|---|---|---|
| CLOVER BIOPHARMACEUTICALS, LTD. | Chief Executive Officer | 25.12.2020 |
Sichuan Clover Biopharmaceuticals, Inc
 Sichuan Clover Biopharmaceuticals, Inc Pharmaceuticals: MajorHealth Technology Sichuan Clover Biopharmaceuticals, Inc is a clinical-stage biotechnology company based in Chengdu, China. Clover Biopharmaceuticals' mission is to leverage their trimer-tag technology and in-house manufacturing capabilities to develop and deliver innovative and affordable medical solutions. The Chinese company is committed to partnering with leading healthcare organizations to advance their breakthrough pipeline programs and deliver them to patients. The company's pipeline includes many vaccine and therapeutic candidates for the treatment of infectious disease, cancer, and autoimmune disease, created using trimer-tag platform technology. The company was founded in 2007 by Peng Liang, and Joshua Liang has been the CEO of the company since 2016. | Chief Executive Officer | 01.06.2020 |
| Zhejiang Clover Biopharmaceutical, Inc. | Chief Executive Officer | 01.08.2016 |
| Clover Biopharmaceutical Beijing Co. Ltd. | Chief Executive Officer | 01.08.2020 |
| Clover Biopharmaceuticals Shanghai Co. Ltd. | Chief Executive Officer | 01.02.2021 |
| Clover Biopharmaceuticals USA, Inc. | Chief Executive Officer | 01.04.2020 |
| Clover Biopharmaceuticals Aus Pty Ltd. | Chief Executive Officer | 01.12.2020 |
| Clover Biopharmaceuticals Hong Kong Ltd. | Director/Board Member | 01.12.2020 |
Ausbildung von Joshua Liang
| University of Pennsylvania | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CLOVER BIOPHARMACEUTICALS, LTD. | Health Technology |
| Private Unternehmen | 7 |
|---|---|
Sichuan Clover Biopharmaceuticals, Inc
Sichuan Clover Biopharmaceuticals, Inc Pharmaceuticals: MajorHealth Technology Sichuan Clover Biopharmaceuticals, Inc is a clinical-stage biotechnology company based in Chengdu, China. Clover Biopharmaceuticals' mission is to leverage their trimer-tag technology and in-house manufacturing capabilities to develop and deliver innovative and affordable medical solutions. The Chinese company is committed to partnering with leading healthcare organizations to advance their breakthrough pipeline programs and deliver them to patients. The company's pipeline includes many vaccine and therapeutic candidates for the treatment of infectious disease, cancer, and autoimmune disease, created using trimer-tag platform technology. The company was founded in 2007 by Peng Liang, and Joshua Liang has been the CEO of the company since 2016. | Health Technology |
| Clover Biopharmaceuticals USA, Inc. | |
| Zhejiang Clover Biopharmaceutical, Inc. | |
| Clover Biopharmaceuticals Aus Pty Ltd. | |
| Clover Biopharmaceuticals Hong Kong Ltd. | |
| Clover Biopharmaceutical Beijing Co. Ltd. | |
| Clover Biopharmaceuticals Shanghai Co. Ltd. |
